Skip to content
Narrow screen resolution Wide screen resolution Increase font size Decrease font size Default font size
Home Page arrow Divisions arrow Radiological Sciences and Radiopharmaceuticals
Radiological Sciences and Radiopharmaceuticals PDF Print E-mail
Article Index
Radiological Sciences and Radiopharmaceuticals
Page 2
Page 3
Page 4
Page 5
Page 6



  • Peptide-based radiopharmaceuticals: Radiolabeled somatostatin, bombesin, neurotensin, gastrin and other peptide-based analogs have been and will continue to be developed and screened as candidates for receptor-targeted diagnostic tumor imaging using SPECT and PET, as well as for peptide receptor targeted therapy (PRTT).
  • Selected analogs are undergoing Phase I clinical trials in European clinical centers (Austria, UK, Germany, Italy and The Netherlands).
  • Neuroprotective peptides (humanin, colivelin), alpha-thymosins (inflammation imaging) and anti-microbial peptides (infection imaging) labeled with Tc-99m via different chelating systems.
  • Bioinorganic compounds: New mixed ligand chelating systems for technetium, rhenium and other metals in different oxidation states.
  • Radiolabeled small bioactive molecules: Pharmacophore- (quinazolines for EGFR imaging, cationic compounds for targeting of energized mitochondria, quinolones for discrimination of infection from aseptic inflammation) coupled (radio)metal chelates, mainly 99mTc-based.
  • Antibodies: Monoclonal Antibodies labeled with gamma-, beta- and positron-emitting radioisotopes (Technetium-99m, Rhenium-186/188, Lutetium-177, Samarium-153, Arsenic-74, Niobium-90) for targeted imaging and therapy of cancer.
  • Nanoparticles: Multimodal (SPECT/PET/Optical) mannosylated dextrans for sentinel lymph node detection; Gd-based nanoparticle structures (iron-oxide/gold) labeled with Gallium-68, as dual-modality imaging agents.